Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
Soon after FDA approved generic versions of epinephrine injection USP (EpiPen, Mylan and Pfizer), a pharma maker is releasing a generic EpiPen for children.
Teva Pharmaceutical Industries said the FDA-approved version of EpiPen Jr. 0.15 mg is now available in most retail pharmacies. Teva’s generic version costs $300 per 2-pack.
Related: Epipen Shortage: Pharma Maker, Retailer Offer Aid
A year ago, FDA cleared the first generic version of epinephrine, granting Teva authority to make generic versions in 0.3 mg and 0.15 mg strengths.
“This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages.” said former FDA Commissioner Scott Gottlieb, MD, in a statement from FDA, at the time.
Related: Generic Epipen Poised To Alleviate Shortages
There is still a shortage of EpiPens in the U.S., Europe, and Canada. In fact, Pfizer and Mylan worked with FDA in June to extend the expiration dates by four months of all lots of EpiPen Auto-Injectors and its authorized generic version currently on the market in the US.
“Patients should have confidence in using the products as Pfizer works to stabilize supply,” Pfizer and Mylan said in a joint press release.
Meanwhile, Teva will continue working to ensure availability of both generic EpiPen strengths in the US and plan to accelerate production to meet the urgent need for this medicine,” said Brendan O’Grady, EVP and head of North America Commercial for Teva, in a statement.
Read more: FDA approves EpiPen rival
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More